Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM).

about

Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM).

Item

http://www.wikidata.org/entity/Q47217258

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM).

@en

Highlights of the season 2016–2017 by the Spanish Melanoma Group

@nl

type

Item

label

Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM).

@en

Highlights of the season 2016–2017 by the Spanish Melanoma Group

@nl

prefLabel

Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM).

@en

Highlights of the season 2016–2017 by the Spanish Melanoma Group

@nl

P1476

Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)

@en

P2093

Ainara Soria

http://www.w3.org/2001/XMLSchema#string

Alfonso Berrocal

http://www.w3.org/2001/XMLSchema#string

Enrique Espinosa

http://www.w3.org/2001/XMLSchema#string

Jose Luis Manzano

http://www.w3.org/2001/XMLSchema#string

Maria Gonzalez-Cao

http://www.w3.org/2001/XMLSchema#string

Salvador Martin-Algarra

http://www.w3.org/2001/XMLSchema#string

P2860

Immune checkpoint inhibitors: therapeutic advances in melanoma

Hepatotoxicity with combination of vemurafenib and ipilimumab

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

P31

scholarly article

P356

10.21037/ATM.2017.06.37

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

I Marquez-Rodas

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P932

5653512

http://www.w3.org/2001/XMLSchema#string